The same team did [3H]UCB-J autoradiography of brain sections from an early model of Parkinson’s disease induced by unilateral intranigral injection of recombinant adeno-associated viral vectors expressing the human α-synuclein protein, but did not find changes of SV2A density in the striatum or substantia nigra in this early model, despite the reduction of dopaminergic pre-synaptic terminal markers including the dopamine transporter and the vesicular monoamine transporter 2 (Stokholm et al., 2021). This evidence concerns the gene SV2A and Parkinson disease.